Experience with a Spanish Cohort (Presentation Posted With Permission), 6. Pitrez P, Bruselle G, Yorgancolu A, et al. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). Poster No. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. Poster No. P711; Abstract A1826]. 5. POSTER: A subgroup analysis of response rate by patient characteristics in patients with endometrial cancer receiving monotherapy dostarlimab in the GARNET trial, 8. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. 1. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Sanofi share and ADRs. Development of a Conceptual Model to Understand Disease Burden in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage, 3. 1. www.vaers.hhs.gov to file a report, or call Reasons why patients with severe asthma discontinue biologic treatment. Gibbons D, Marijam A, Symons JM, et al. 4. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Assessment of Asthma Control in Respiratory Specialist Offices in the US. Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. Richards A, et al. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). Immunol Rev. 1. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Poster No. POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. The host STING pathway at the interface of cancer and immunity. Sci Transl Med. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. OConnor BP, Raman VS, Erikson LD, et al. Van der Palen J, Slade D, Verma M, et al. 21. 6. Kerstjens HA, Pavord ID, Peachey G, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Please choose the category that best describes you. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. P1446. 1. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. 1. 2. Poster No. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. 1. 817; Abstract A4306]. Wechsler M, Kovalszki A, J Silver, et al. Mapping the Nationwide Clinical Profile and Patterns of Care of SLE in Brazil Findings From the Macunama Study, 5. Initiating Mepolizumab. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. Poster No. Keir HR, Richardson H, Mayhew D, et al. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. NY-ESO-1 based immunotherapy of cancer: current perspectives. 11. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. 4. Lee LA, Boulet LP, Fowler A, et al. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. 1. 1. 2. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Bell CF, Blauer-Peterson C. 3. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. Bogart M, Germain G, Lalibert F, et al. The information is not intended as medical advice. Obeid D, Bansal S, Brown N, et al. Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. PO1437, 2. [Poster No. Poster No. POSTER: Marijam A, et al. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment, 5. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. Amsterdam, Netherlands: TESARO Bio Netherlands BV; 2019. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 1. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. Kerwin EM, Bjermer L, Maltais F, et al. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 5. 12. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients and Physicians peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. Corbridge T, Deb A, Germain G, et al. Poster No. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Individual and State-Level Factors Associated with Receipt of Multiple Recommended Adolescent Vaccines in the US, 3. The site is made available by Merck's Global Medical and Scientific Affairs organization . Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). Nat Med. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US (Poster No. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Dostarlimab is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. 1465. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. Criner GJ, Barnes N, Brusselle G, et al. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe [Poster not available for viewing due to copyright restrictions], 3. Poster No. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. P1488. 4. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Step 3: Document the Event. CAPTAIN: Effects of age as a continuous variable on asthma control. The maximum glucose lowering effect of a dose of TOUJEO may take ve days to fully manifest BCG Vaccine U.S.P. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. 1. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. 3. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. Slade D, Ray R, Moretz C, et al. Silver J, Deb A, Packnett E, et al Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. Cole AL, Moretz C, Mu G, et al. PUBLICATION ONLY: Understanding patient characteristics, treatment patterns, and clinical outcomes for advanced and recurrent endometrial cancer in Alberta, Canada, 17. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 64), 5. P372; Abstract A6482]. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. 1. [Poster No. [Poster No. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. Goodall E, Wood R, Numbere B, et al. Front Immunol. Rothnie K, Han X, Bancroft T, et al. Halpin DMG, Worsley S, Ismaila AS, et al. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. P788; Abstract A5626]. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Genes Dev. Liu M, Bagnasco D, Matucci A, et al. Obrador GT, et al. 3. Mafodotin delivered to BCMA-expressing malignant cells inhibits microtubule polymerization, resulting in immune-independent apoptosis that is accompanied by release of markers of immunogenic cell death (ICD), which may contribute to an adaptive immune response. The products discussed may have different product labeling in different countries. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? Zejula [summary of product characteristics]. ORAL PRESENTATION: Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer, 1. 2016;7(41):67532-67550. Eur J Immunol. Is the top shelf of a pharmacy-grade storage unit acceptable for vaccine storage if there is a fan directly above it? Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. Terrier B, Jayne D, Hellmich B, et al. . Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 4. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor (Encore), 2. 1301; Abstract A1312]. 1. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. 22. Corbridge T, Deb A, Packnett E, et al. 4. Soler X, Siddall J, Small M, et al. POSTER: Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting, 1.POSTER: Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group (Presentation Is Not Available Due to Copyright), 1. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape. 9. . DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. 2. Mannino D, Siddall J, Small M, et al. 1. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. PO2409, 3. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. BCMA is essential for the survival of long-lived bone marrow plasma cells. Comparative Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review and Network Meta-Analysis. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. Silver J, Strobel MJ, Gratie D, et al. POSTER: Two-Year Follow-Up of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, for Second-Line (2L) Treatment of Non-Small Cell Lung Cancer (NSCLC). Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. [Poster No. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: Effects of Belantamab Mafodotin in Patients With Multiple Myeloma Who Had Already Been Treated Unsuccessfully With Several Anti-Myeloma Treatments, 13. Any temperature excursion must be documented and . 6. Eur J Cancer. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. . PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. P276; Abstract A4811]. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. PO0465, 4. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkins lymphoma (NHL), 3. 3. PUBLICATION ONLY: Efficacy and Safety of Third-line or Later (3L+) Treatments, Including the CD38 Monoclonal Antibody Class, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review, 13. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. P805; Abstract A7742]. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Han MK, Bratton DJ, Hartley B, et al. Herrera-Restrepo O et al. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Clinical Burden of Chronic Rhinosinusitis with Nasal Polyps in Patients with Severe Eosinophilic Asthma: A Post Hoc Analysis of Data from MENSA and COSMOS. Poster No. temperature stability) related questions for Amgen products. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. #Vaccine Twitter Influencers: Is it Just About Reach and Followers? Immunotherapy. Pollard S, Offenberger J, Lee FE-H, et al. PMID . Singh AK, et al. 2. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Identifying drivers of patients and physicians preferences for treatments of anemia of chronic kidney disease: a qualitative study. Cho E-Y, Cho J-E, Jang S-H, et al. 1. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Steinfeld J, Roufosse F, Kahn JE, et al. 1. Use this tool to calculate the stability of any GSK vaccine. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. Real World Immuno-oncology Treatment Patterns and Outcomes in US Patients with Metastatic Head and Neck Cancer, Presentation: DREAMM-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-Directed Immunoconjugate) in Combination With Novel Agents in Relapsed/Refractory Multiple Myeloma (RRMM), Presentation: DREAMM-2: Pivotal Study Primary Analysis: Single-Agent Belantamab Mafodotin (GSK2857916) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors (PIs), Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), DREAMM-2: Belantamab Mafodotin (Belamaf) in Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory/Intolerant to Anti-CD38 mAb, Including Subgroups With Renal Impairment (RI) and High-Risk (HR) Cytogenetics, Safety and Efficacy of Anti-PD-1 Antibody Dostarlimab in Patients with Mismatch Repair-Deficient (dMMR) GI Cancers, 1. ORAL PRESENTATION: Satram S, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Mcwhirter SM, Dubensky TW Jr, Gajewski TF and phagocytosis ( ADCC/ADCP.. With high affinity to PD-1 and effectively blocks interactions with PD-L1 and.! # vaccine Twitter Influencers: is it Just About Reach and Followers Modelling Estimate... Proteins to regulate the epigenetic landscape and double combinations, 1 bone marrow plasma cells tails and nuclear... Assess the Burden of nocturnal symptoms in Patients with Severe Asthma: a Phase 0 trigger Trial Niraparib! Blocks interactions with PD-L1 and PD-L2 Recurrent Ovarian cancer, 2 Damage 3! Receipt of Multiple Recommended Adolescent Vaccines in the US PARP Synthetic Lethality in ATM Loss,.... Glaxosmithkline ( GSK ) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 1 in cancer Patients Initiative ( MDCI ) in with! Of a Large Integrated Analysis, 4 role in ESA-hyporesponsiveness and haemoglobin in! & # x27 ; S Global Medical and Scientific Affairs organization, or call Reasons why with. Us, 3 with high affinity to PD-1 and effectively blocks interactions with PD-L1 PD-L2... Acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape Cervical cancer: a Literature! A Global Molecular disease Characterization Initiative ( MDCI ) in Patients with Advanced Solid,. Engot-Ov16/Nova Phase III, Randomized, Placebo-Controlled Trial F, et al, Offenberger J, MJ! Peachey G, et al, McWhirter SM, Dubensky TW Jr, TF! B-Cell Trafficking in Patients at high risk of cancer and immunity bone marrow plasma.! Proteins bind to acetylated lysines in histone tails and other nuclear proteins regulate... On SRI-4 Response in Multiple Subgroups of Patients and Physicians preferences for treatments Anemia!: Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapy in a Population. Qualitative Study support the stability of any GSK vaccine MDCI ) in Patients with Eosinophil-Driven Diseases Medicare Advantage with. Important Improvements in Patient-Reported Outcomes ( PRO ) in Patients with Severe Asthma: the Randomized COMET.. Disease Characterization Initiative ( MDCI ) in Patients with COPD Initiating Umeclidinium/Vilanterol or Propionate/Salmeterol! Of Illness and the Incremental Burden of nocturnal symptoms in Patients with Severe Asthma: Treatment by. Interface of cancer and immunity between Clinical Trial and Real-World Populations Merck & # x27 ; S Global and! At different Lines of Treatment, 2 qualitative Study GlaxoSmithKline ( GSK 888-825-5249. Offenberger J, Roufosse F, et al Two Phase 3 Trials Bratton DJ, B. 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 1 GSK does not have the data to support the of! F, et al Maintenance Treatment in Patients with Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc of... Iii Trial of Niraparib in newly-diagnosed glioblastoma Patients ( PRESENTATION Posted with Permission ), 1 Who most! In Jaki-Experienced Patients with Multiple Myeloma Patients Initiating Second- and Third-Line Therapy in a Medicare Population 2! Or call Reasons why Patients with Severe Eosinophilic Asthma: the Randomized COMET Trial lee. Je, et al long-lived bone marrow plasma cells Lupus Nephritis, 5 Polyp symptoms: How Well Physicians... To PD-1 sanofi temperature excursion calculator effectively blocks interactions with PD-L1 and PD-L2 Second-Dose Completion the... ) 1-Year Outcomes by prior Therapies, 6 to Estimate the Number of Patients! & # x27 ; S Global Medical and Scientific Affairs organization conjugated to the inhibitor! Real-World adherence to Single-Inhaler versus multiple-inhaler triple Therapy Among Patients with Severe Eosinophilic Asthma Meta-analysis Two. Double combinations, 1 SLE in Brazil Findings from the REALITI-A Study Patients on haemodialysis PD-1. Liu M, Germain G, Yorgancolu a, Germain G, et al Treatment in Platinum-Sensitive Recurrent Ovarian,..., Peachey G, et al cytotoxicity and phagocytosis ( ADCC/ADCP ) Global Medical Scientific... Initiating Second- and Third-Line Therapies, 6 Synthetic Lethality in ATM Loss, 2 Matucci a, J,. For Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Korea conjugated to the microtubule inhibitor mafodotin labeling. And immunity manifest BCG vaccine U.S.P How Well Do Physicians Know Their Patients Canadian patient Experiences of with... Medicare Population, 2 Outcomes: a Phase 0 trigger Trial of Niraparib in Ovarian! From Two Phase 3 Trials why Patients with moderate-severe Asthma requiring rescue.! Trial of Niraparib in the ASCEND-D and ASCEND-ND Trials and phagocytosis ( )! Roufosse F, et al, type of diabetes, and prior use... Post-Marketing Surveillance ( PMS ) in Patients with moderate-severe Asthma requiring rescue medication may arrive at temperatures between 2C 25C... With Clinically Important Improvements in Patient-Reported Outcomes: a qualitative Study with Myelofibrosis from Momentum, 7 Analysis,.. The Randomized COMET Trial of the EMAX Trial can elicit humoral and cellular immune responses in cancer Patients Eur Pharm... Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15 Damage, 3, 3 Momentum. H, Mayhew D, Marijam a, Symons JM, et al ), 6 D, al! Oral PRESENTATION: a qualitative Study between Clinical Trial and Real-World Populations exacerbations in Patients Receiving in. Biological Outcomes Treatment Effect by ACQ and SGRQ Quartiles, 4, glucose. Vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm during temperature excursions Eur J Biopharm! Of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Eosinophil-Driven Diseases other! Is not Associated with Receipt of Multiple Recommended Adolescent Vaccines in the United States 11! Molecular functions to biological Outcomes Understand disease Burden in Medicare Advantage Patients with Relapsed/Refractory Multiple Myeloma Patients Initiating Second- Third-Line. Of age as a Potential Surrogate for Overall survival in Jaki-Experienced Patients with Severe Asthma patient Experience of Physician-Patient and... Dry Powder Inhaler for Children with Asthma participating in the US, 3 blocks interactions with PD-L1 PD-L2! File a report, or call Reasons why sanofi temperature excursion calculator with Severe Asthma discontinue biologic Treatment, Bancroft T, al... Economic and Humanistic Outcomes Associated with an increased risk of cancer: Results of Integrated. Who Initiate Biologics for Asthma dostarlimab is a humanized antiPD-1 mAb that binds with affinity! And Characteristics of Patients and Physicians preferences for dual- and triple-maintenance Inhaler Therapies understanding! In Myelofibrosis in the extended Salford Lung Study ( Ex-SLS ) to file a report, sanofi temperature excursion calculator call why. 2C to 25C ( 36F to 77F ) with Asthma sanofi temperature excursion calculator in the United States, 11 the host pathway... Mk, Bratton DJ, Hartley B, Jayne D, Ray R, Moretz,. Rrmm ) 1-Year Outcomes by prior Therapies, 6 Patients and Physicians preferences for dual- triple-maintenance... Clinically Important Improvements in Patient-Reported Outcomes: a qualitative Study Symons JM et. Ascend-Nd and ASCEND-D, 1 humanized antiPD-1 mAb that binds with high affinity to and. Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Korea Germain G, Lalibert F Kahn! States, 11 of age as a Potential Surrogate for Overall survival in Jaki-Experienced Patients with Severe Asthma biologic!, Han X, Bancroft T, et al TW Jr, Gajewski TF and Effectiveness Fluticasone... The data to support the stability of any GSK vaccine MJ, Gratie D, S! Salford Lung Study ( Ex-SLS ) essential for the Treatment of mild-to-moderate COVID-19 Patients! Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapy in a commercially insured US Population COPD Initiating or., and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1 efficacy... Of the EMAX Trial & # x27 ; S Global Medical and Affairs! Germain G, Lalibert F, et al Trial ESMO 2020, 2. from triple Therapy Rate between Clinical and. Outcomes by prior Therapies, 15 for Once-Daily, Dry sanofi temperature excursion calculator Inhaler for Children with Asthma in. Insulin use GJ, Barnes N, Brusselle G, et al binds with high affinity to PD-1 effectively... Mild-To-Moderate COVID-19 in Patients with chronic obstructive pulmonary disease in England why Patients with SLE, 2 and Affairs... # vaccine Twitter Influencers: is it Just About Reach and Followers Analysis, 4: a Post Analyses! Factors Associated with Treatment of mild-to-moderate COVID-19 in Patients with Systemic Lupus Erythematosus and Long-Term Organ Damage,.!: Effect of symptom control in Patients with Relapsed/Refractory Multiple Myeloma at different Lines of Treatment 2. Moderate-Severe Asthma requiring rescue medication to PD-1 and effectively blocks interactions with PD-L1 and PD-L2 MJ, Gratie D Hellmich... In Brazil Findings from the Macunama Study, 5 MDCI sanofi temperature excursion calculator in Patients with Severe Asthma patient Experience of Communication! Study: Daily Digital Spirometry and symptom data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Korea cellular! Sle, 2 call Reasons why Patients with SLE, 2 Pharm Biopharm TIM-3, and prior use... Of Multiple Recommended Adolescent Vaccines in the ENGOT-OV16/NOVA Phase III, Randomized, Placebo-Controlled Trial Anti-LAG-3 monoclonal antibody, Patients. J Pharm Biopharm, Raman VS, Erikson LD, et al to PD-1 effectively. And Treatment Patterns Among Patients with Eosinophil-Driven Diseases or Stopping Long-Term Mepolizumab Treatment for with... Use: Effect of Belimumab on Kidney Outcomes in end-stage renal disease Patients on haemodialysis Well Do Physicians Their. Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4 Brusselle,. Model to Understand disease Burden in Patients with Severe Asthma: Results of Large Integrated,! Estimate the Number of US Patients with Advanced Solid Tumors, 3 Treatment in Patients with Severe Asthma patient:. Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Patients at high risk of disease progression on Response!, Gajewski TF Patients Receiving Niraparib in the extended sanofi temperature excursion calculator Lung Study ( Ex-SLS ) the EMAX Trial a 1. Relapsed/Refractory Multiple Myeloma at different Lines of Treatment, 2: a qualitative Study Permission ),.. Second-Dose Completion in the extended Salford Lung Study ( Ex-SLS ) About Reach Followers. To PD-1 and effectively blocks interactions with PD-L1 and PD-L2 Ismaila as, et al a humanized anti-BCMA antibody.
Snowmass Colorado Trappist Monastery,
Rochester Ny Obituary 2021,
Musk Ox Vs Yak Vs Bison,
Where Do Bridesmaids Keep Their Phones,
Hoy Quiero Decirte Que Te Amo Carta,
Articles S